Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 14,437 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard-of-Care Clear all
Completed No phase listed Observational Results available

Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)

NCT03257254
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
Varithena
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Timeline
2017 – 2020
U.S. locations
13
States / cities
Palo Alto, California • Sacramento, California • Darien, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 15, 2026, 1:29 AM EDT
Active, not recruiting Not applicable Interventional

Patient Perceptions of the Relational Empathy of Healthcare Practitioners From the Department of Emergency Medicine During the COVID-19 Pandemic

NCT05102656
View directory record Official record
Conditions
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Best Practice, Discussion, Questionnaire Administration
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 15, 2026, 1:29 AM EDT
Recruiting Phase 2 Interventional

Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation

NCT06799195
View directory record Official record
Conditions
Hematological Malignancies, Graft-versus-Host Disease (GVHD)
Interventions
Attenuated-dose Cyclophosphamide, High-dose Cyclophosphamide, Sirolimus, Mycophenolate Mofetil (MMF)
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
60 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 1:29 AM EDT
Completed Phase 2 Interventional Results available

Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors

NCT00003475
View directory record Official record
Conditions
Malignant Brain Tumors
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 15, 2026, 1:29 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

NCT02312557
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Hormone-Resistant Prostate Cancer, PSA Progression, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma Cancer AJCC v8
Interventions
Enzalutamide, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Other · Biological
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 15, 2026, 1:29 AM EDT
Completed Not applicable Interventional

A Systematic Oral Care Program in Post-Mechanically Ventilated, Post-Intensive Care Patients

NCT03886623
View directory record Official record
Conditions
Methicillin-resistant Staphylococcus Aureus, Methicillin-Sensitive Staphylococcus Aureus Infection
Interventions
4-day systematic oral hygiene, Standard of Care oral care
Procedure · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 15, 2026, 1:29 AM EDT
Not listed Not applicable Interventional

Trial Comparing SOC +Skin IQ MCM vs SOC for Pressure Ulcer (PU)

NCT02363842
View directory record Official record
Conditions
Pressure Ulcer
Interventions
Skin IQ™ MCM Coverlet, Pressure redistribution surface
Device · Other
Lead sponsor
Arjohuntleigh
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Oklahoma City, Oklahoma • Dallas, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2015 · Synced Oct 15, 2026, 1:29 AM EDT
Active, not recruiting Phase 1 Interventional

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

NCT03690986
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
VX15/2503, Ipilimumab, Nivolumab
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 15, 2026, 1:29 AM EDT
Terminated Not applicable Interventional

Effect of Lost Wage Reimbursement to Kidney Donors on Living Donation Rates

NCT03350269
View directory record Official record
Conditions
Kidney Failure, Surgery, Renal Failure
Interventions
Information provision
Other
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
18 Years and older
Enrollment
1,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Los Angeles, California • Denver, Colorado • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Oct 15, 2026, 1:29 AM EDT
Terminated Phase 4 Interventional Results available

Oral Anti Diabetic Agents in the Hospital

NCT04416269
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM)
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 15, 2026, 1:29 AM EDT
Terminated Not applicable Interventional

A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®)- for Maintaining Bowel Regularity in Patients With GI Toxicity From Any Combination of Therapy Including Tyrosine Kinase Inhibitors (TKI)

NCT02381405
View directory record Official record
Conditions
Diarrhea
Interventions
Enterade beverage
Dietary Supplement
Lead sponsor
GenesisCare USA
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 15, 2026, 1:29 AM EDT
Terminated Phase 2 Interventional Results available

A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1

NCT04059094
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
BI 1265162, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Orlando, Florida • Indianapolis, Indiana • Chapel Hill, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Oct 15, 2026, 1:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vouchers to Increase Uptake of Already Free Eye Care

NCT04426331
View directory record Official record
Conditions
Glaucoma, Eye Diseases
Interventions
Voucher Without Value Information, Voucher With Value Information
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
739 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 15, 2026, 1:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The YourMove Study: Optimizing Individualized and Adaptive mHealth Interventions Via Control Systems Engineering Methods

NCT05598996
View directory record Official record
Conditions
Inactivity, Physical, Sedentary Behavior
Interventions
COT-Based Intervention
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
25 Years to 80 Years
Enrollment
386 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 15, 2026, 1:29 AM EDT
Completed Not applicable Interventional

Acceptance and Commitment Therapy for Chronic Pain in Integrated Primary Care

NCT04978961
View directory record Official record
Conditions
Chronic Pain
Interventions
Focused Acceptance & Commitment Therapy (FACT), Enhanced Treatment as Usual (ETAU)
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 99 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 15, 2026, 1:29 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Clinical Performance of the Investigational GEM Hemochron® 100 in Populations Ages 18 Years and Older

NCT03074266
View directory record Official record
Conditions
Blood Coagulation Test
Interventions
GEM Hemochron 100 ACT
Diagnostic Test
Lead sponsor
Accriva Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
9
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 15, 2026, 1:29 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

NCT02955394
View directory record Official record
Conditions
Breast Cancer
Interventions
Enzalutamide, Fulvestrant
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 101 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
3
States / cities
Aurora, Colorado • New York, New York • Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 15, 2026, 1:29 AM EDT
Recruiting Phase 1Phase 2 Interventional

SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases

NCT04923542
View directory record Official record
Conditions
Brain Metastases, HR+ Metastatic Breast Cancer
Interventions
Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Tampa, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 15, 2026, 1:29 AM EDT
Terminated Phase 2 Interventional Results available

Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

NCT04373369
View directory record Official record
Conditions
Extensive-stage Small Cell Lung Cancer
Interventions
Vorolanib, Atezolizumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 15, 2026, 1:29 AM EDT
Not yet recruiting Not applicable Interventional

A Multi-Site Hybrid Type I Effectiveness-Implementation Randomized Trial of an Emergency Care Action Plan for Infants With Medical Complexity

NCT06993129
View directory record Official record
Conditions
Chronic Disease Management, Infants Health, Emergency, Utilization, Health Care, Caregiver Stress
Interventions
Emergency Care Action Plan
Other
Lead sponsor
University of Vermont
Other
Eligibility
0 Months to 6 Months
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Aurora, Colorado • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 15, 2026, 1:29 AM EDT
Recruiting Phase 4 Interventional

Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease

NCT07280702
View directory record Official record
Conditions
Psoriatic Arthritis (PsA)
Interventions
Deucravacitinib, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 15, 2026, 1:29 AM EDT
Completed Not applicable Interventional

Practical Alternative to Hospitalization

NCT04639102
View directory record Official record
Conditions
Emergency Department, Health, Subjective, Health Care Utilization
Interventions
PATH Intervention
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 15, 2026, 1:29 AM EDT
Completed Not applicable Interventional

A Survivorship Care Plan and Embedded Navigation Tool

NCT03424837
View directory record Official record
Conditions
Prostate Cancer
Interventions
ASCENT
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 15, 2026, 1:29 AM EDT
Completed Phase 4 Interventional Results available

Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients

NCT02152345
View directory record Official record
Conditions
Implant or Graft; Rejection
Interventions
Belatacept, Tacrolimus, Mycophenolate, rATG, Methylprednisolone, Renal transplant
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 15, 2026, 1:29 AM EDT